CRISPR Therapeutics AG CRSP

Company Overview

CRISPR Therapeutics AG is a clinical-stage biotechnology company focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing platform. The company operates within the biotechnology and life sciences industries, with a primary emphasis on gene editing therapies for serious diseases. Its core revenue drivers to date are collaboration and license revenues, milestone payments, and, more recently, product-related revenue tied to its first commercial therapy.

The company is best known for the development of CASGEVY (formerly exa-cel), a CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia, developed in partnership with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, one of the pioneers of CRISPR/Cas9 technology, and has since evolved from a research-focused organization into a late-stage clinical and early commercial biotechnology company following regulatory approvals in multiple major markets.